Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.

Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.

The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.

China's biopharma firms including Hengrui Medicine and HUTCHMED actively pursue licensing partners for their drug assets as the economic downturn caused by domestic COVID flare-ups continues worsening. Meanwhile, there are some predictions that smaller biotechs in the country may need to tap into multinationals' deep pockets to raise new funds.